We feel now is a pretty good time to analyse Sernova Biotherapeutics Inc's (TSE:SVA) business as it appears the company may be on the cusp of a considerable accomplishment. Sernova Biotherapeutics Inc operates as a clinical-stage biotechnology company in Canada. With the latest financial year loss of CA$16m and a trailing-twelve-month loss of CA$12m, the CA$47m market-cap company alleviated its loss by moving closer towards its target of breakeven. Many investors are wondering about the rate at which Sernova Biotherapeutics will turn a profit, with the big question being “when will the company breakeven?” We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.
According to some industry analysts covering Sernova Biotherapeutics, breakeven is near. They anticipate the company to incur a final loss in 2027, before generating positive profits of CA$173m in 2028. The company is therefore projected to breakeven around 2 years from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 61%, which signals high confidence from analysts. Should the business grow at a slower rate, it will become profitable at a later date than expected.
Underlying developments driving Sernova Biotherapeutics' growth isn’t the focus of this broad overview, though, bear in mind that generally a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.
See our latest analysis for Sernova Biotherapeutics
Before we wrap up, there’s one issue worth mentioning. Sernova Biotherapeutics currently has negative equity on its balance sheet. This can sometimes arise from accounting methods used to deal with accumulated losses from prior years, which are viewed as liabilities carried forward until it cancels out in the future. Oftentimes, losses exist only on paper but other times, it can be a red flag.
Next Steps:
There are too many aspects of Sernova Biotherapeutics to cover in one brief article, but the key fundamentals for the company can all be found in one place – Sernova Biotherapeutics' company page on Simply Wall St. We've also put together a list of essential aspects you should further research:
- Historical Track Record: What has Sernova Biotherapeutics' performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Sernova Biotherapeutics' board and the CEO’s background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.